Original Article

You have full text access to this OnlineOpen article

Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree

  1. Alain Gelibter M.D.1,
  2. Paola Malaguti M.S.1,
  3. Serena Di Cosimo M.D.1,
  4. Emilio Bria M.D.2,
  5. Enzo Maria Ruggeri M.D.1,
  6. Paolo Carlini M.D.1,
  7. Fabio Carboni M.D., Ph.D.3,
  8. Giuseppe Maria Ettorre M.D.3,
  9. Mario Pellicciotta M.S.4,
  10. Diana Giannarelli M.S.4,
  11. Edmondo Terzoli M.D.2,
  12. Francesco Cognetti M.D.1,
  13. Michele Milella M.D.1,†,*

Article first published online: 2 AUG 2005

DOI: 10.1002/cncr.21286

Issue

Cancer

Cancer

Volume 104, Issue 6, pages 1237–1245, 15 September 2005

Additional Information

How to Cite

Gelibter, A., Malaguti, P., Di Cosimo, S., Bria, E., Ruggeri, E. M., Carlini, P., Carboni, F., Ettorre, G. M., Pellicciotta, M., Giannarelli, D., Terzoli, E., Cognetti, F. and Milella, M. (2005), Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer, 104: 1237–1245. doi: 10.1002/cncr.21286

Author Information

  1. 1

    Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy

  2. 2

    Division of Medical Oncology C, Regina Elena National Cancer Institute, Rome, Italy

  3. 3

    Division of Digestive Surgery and Liver Transplantation, Regina Elena National Cancer Institute, Rome, Italy

  4. 4

    Division of Biostatistics, Regina Elena National Cancer Institute, Rome, Italy

  1. †

    Fax: (011) 39-06-5266-5637

*Division of Medical Oncology A, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy

Publication History

  1. Issue published online: 31 AUG 2005
  2. Article first published online: 2 AUG 2005
  3. Manuscript Accepted: 11 MAY 2005
  4. Manuscript Revised: 26 FEB 2005
  5. Manuscript Received: 20 OCT 2004

Funded by

  • Italian Ministry of Health. Grant Number: R.F. 02/184

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (108K)

REFERENCES

  • 1
    American Cancer Society. Cancer facts and figures 2004. Atlanta: American Cancer Society, 2004.
  • 2
    Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403–2413.
  • 3
    Tsavaris N, Kosmas C, Gouveris P, et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs. 2004; 22: 193–198.
  • 4
    Lin MH, Chen JS, Chen HH, Su WC. A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy. 2003; 49: 154–158.
  • 5
    Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol. 2001; 19: 4089–4091.
  • 6
    Penz M, Kornek GV, Raderer M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol. 2001; 12: 183–186.
  • 7
    Raderer M, Hejna MH, Valencak JB, et al. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology. 1999; 56: 177–180.
  • 8
    Gallardo JO, Rubio B, Fodor M, et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol. 2001; 12: 1403–1406.
  • 9
    Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology. 2001; 48: 783–789.
  • 10
    Kulke MH. Advanced pancreatic cancer: is there a role for combination therapy? Expert Rev Anticancer Ther. 2003; 3: 729–739.
  • 11
    Pollera CF. More is better but … how is best: are milligrams over hours better than grams over minutes? The case of gemcitabine. J Clin Oncol. 1997; 15: 2172–2174.
  • 12
    Pollera CF, Ceribelli A, Crecco M, Oliva C, Calabresi F. Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels. Invest New Drugs. 1997; 15: 115–121.
  • 13
    Abbruzzese JL. New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer. 2002; 95: 941–945.
    Direct Link:
  • 14
    Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1988; 48: 4024–4031.
  • 15
    Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res. 1990; 50: 6823–6826.
  • 16
    Hughes TL, Hahn TM, Reynolds KK, Shewach DS. Kinetic analysis of human deoxycytidine kinase with the true phosphate donor uridine triphosphate. Biochemistry. 1997; 36: 7540–7547.
  • 17
    Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991; 9: 491–498.
  • 18
    Gandhi V, Plunkett W, Du M, Ayres M, Estey EH. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol. 2002; 20: 665–673.
  • 19
    Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001; 19: 3483–3489.
  • 20
    Ceribelli A, Gridelli C, De Marinis F, et al. Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer. 2003; 98: 337–343.
    Direct Link:
  • 21
    Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003; 21: 3402–3408.
  • 22
    Brand R, Capadano M, Tempero M. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs. 1997; 15: 331–341.
  • 23
    Touroutoglou N, Gravel D, Raber MN, Plunkett W, Abbruzzese JL. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol. 1998; 9: 1003–1008.
  • 24
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47: 207–214.
    Direct Link:
  • 25
    A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med. 2001; 20: 859–866.
    Direct Link:
  • 26
    Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer. 1999; 85: 1261–1268.
  • 27
    Fossella FV, Lippman SM, Shin DM, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol. 1997; 15: 310–316.
  • 28
    Von Hoff DD. Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team. Invest New Drugs. 1996; 14: 265–270.
  • 29
    Csoka K, Liliemark J, Larsson R, Nygren P. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol. 1995; 22: 47–53.
  • 30
    Ziske C, Schlie C, Gorschluter M, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer. 2003; 89: 1413–1417.
  • 31
    Stemmler J, Stieber P, Szymala AM, et al. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie. 2003; 26: 462–467.
  • 32
    Saad ED, Machado MC, Wajsbrot D, et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer. 2002; 32: 35–41.
  • 33
    Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000; 82: 1013–1016.
  • 34
    Okusaka T, Okada S, Sato T, et al. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Hepatogastroenterology. 1998; 45: 867–872.
  • 35
    Katz A, Hanlon A, Lanciano R, Hoffman J, Coia L. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys. 1998; 41: 393–396.
  • 36
    Milella M, Gelibter A, Di Cosimo S, et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer. 2004; 101: 133–138.
    Direct Link:
View Full Article (HTML) Get PDF (108K)